18 May 2022 , 07:51 AM
Result date: 19th May, 2022
Recommendation: Buy
Target price: Rs5,000
Dr. Reddy’s Laboratories (Dr. Reddy’s) could witness 3% sequential growth in its US revenues during the March 2022 quarter. It has captured ~13.5% market share in Vascepa during the quarter under review, up from ~9% in December 2021, i.e. its market share has almost trebled from ~4.5% in the June 2022 quarter. According to IU data, Dr. Reddy’s launched Vasostrict AG in February 22 and has garnered ~8% market share in the Vasostrict injectable vials market. This product will be key to the growth of US revenues during the quarter.
The company’s revenue could grow 7%, EBITDA 8% and Profit After Tax (PAT) 15% as compared to the year-ago quarter.
Important management insights to watch out for:
· Outlook on the generic API business
· New launch pipeline
· Likely full contribution from new launches
· Strategy to gain market share
Rs Million | March 2022 estimates | YoY change | QoQ change |
Revenue | 50,746 | 7% | (5)% |
EBITDA | 10,915 | 8% | (9)% |
Profit After Tax | 6,253 | 15% | (12)% |
Source: IIFL Research
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.